U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23N3O5
Molecular Weight 421.4458
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPOTECAN

SMILES

CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC(O)=C(CN(C)C)C5=C4)C2=O

InChI

InChIKey=UCFGDBYHRUNTLO-QHCPKHFHSA-N
InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H23N3O5
Molecular Weight 421.4458
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020671s021lbl.pdf

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. DNA topoisomerases are enzymes in the cell nucleus that regulate DNA topology (3-dimensional conformation) and facilitate nuclear processes such as DNA replication, recombination, and repair. During these processes, DNA topoisomerase I creates reversible single-stranded breaks in double-stranded DNA, allowing intact single DNA strands to pass through the break and relieve the topologic constraints inherent in supercoiled DNA. The 3'-DNA terminus of the broken DNA strand binds covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the unaltered topoisomers that allow transcription to proceed. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug. Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. Topotecan is used for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is sold under the trade name Hycamtin.

CNS Activity

Curator's Comment: freely crosses the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1028.0 nM [IC50]
3.16 µM [IC50]
0.448 µM [IC50]
1.1 µM [IC50]
33.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.1 ng/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.9 ng/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9.29 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
210.5 nM × h
1.25 mg/m² single, intravenous
dose: 1.25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
262.7 nM × h
1.5 mg/m² single, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
304.3 nM × h
2 mg/m² single, intravenous
dose: 2 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
379.6 nM × h
1.75 mg/m² single, intravenous
dose: 1.75 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
49.3 ng × h/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
60.7 ng × h/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
61 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
1.25 mg/m² single, intravenous
dose: 1.25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.7 h
1.5 mg/m² single, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.7 h
2 mg/m² single, intravenous
dose: 2 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.5 h
1.75 mg/m² single, intravenous
dose: 1.75 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6 h
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.6 h
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.23 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
22.2%
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
14.8%
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
65%
TOPOTECAN plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 1 patient)
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 7 patients)
Leukopenia (grade 4, 2 patients)
Neutropenia (grade 2, 6 patients)
Neutropenia (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 1, 2 patients)
Thrombocytopenia (grade 2, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Thrombocytopenia (grade 4, 2 patients)
Anemia (grade 1, 3 patients)
Anemia (grade 2, 3 patients)
Anemia (1 patient)
Sources:
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 4 patients)
Leukopenia (grade 2, 4 patients)
Leukopenia (grade 3, 3 patients)
Leukopenia (grade 4, 1 patient)
Neutropenia (grade 1, 1 patient)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 2, 3 patients)
Thrombocytopenia (grade 3, 2 patients)
Anemia (grade 1, 4 patients)
Anemia (grade 2, 1 patient)
Anemia (grade 3, 1 patient)
Anemia (3 patients)
Sources:
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 3, 40.7%)
Leukopenia (grade 4, 15.9%)
Neutropenia (grade 3, 31%)
Neutropenia (grade 4, 50.4%)
Thrombocytopenia (grade 3, 17.7%)
Thrombocytopenia (grade 4, 22.1%)
Anemia (grade 3, 26.5%)
Anemia (grade 4, 2.7%)
Nausea (grade 1, 31.9%)
Nausea (grade 2, 25%)
Nausea (grade 3, 5.2%)
Alopecia (grade 1, 19.8%)
Alopecia (grade 2, 22.4%)
Alopecia (grade 3, 4.3%)
Fatigue (grade 1, 22.4%)
Fatigue (grade 2, 10.3%)
Fatigue (grade 3, 5.2%)
Vomiting (grade 1, 12.1%)
Vomiting (grade 2, 19.8%)
Vomiting (grade 3, 4.3%)
Vomiting (grade 4, 0.9%)
Diarrhea (grade 1, 19%)
Diarrhea (grade 2, 13.8%)
Diarrhea (grade 3, 1.7%)
Diarrhea (grade 4, 0.9%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 4, 58%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Thrombocytopenia, Anemia...
Other AEs:
Thrombocytopenia (grade 4, 20%)
Anemia (grade 3-4, 11%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 1, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 1, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 1, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 2, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 2, 6 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 3, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 3, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 3, 7 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 4, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 1, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 2, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 2, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 2, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 2, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 3, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 3, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Vomiting grade 1, 12.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 1, 19%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 1, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 1, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 1, 31.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 2, 10.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 2, 13.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 2, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 2, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 2, 25%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 3, 1.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Thrombocytopenia grade 3, 17.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Anemia grade 3, 26.5%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 3, 31%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Leukopenia grade 3, 40.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Leukopenia grade 4, 15.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Anemia grade 4, 2.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Thrombocytopenia grade 4, 22.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 4, 50.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 4, 58%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anemia grade 3-4, 11%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Thrombocytopenia grade 4, 20%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Phase II study of oral topotecan in advanced non-small cell lung cancer.
2000 Mar
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
2001
Treatment of extensive stage small cell lung cancer.
2001
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.
2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
2001 Apr
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
2001 Apr
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
2001 Apr 1
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
2001 Apr 1
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
2001 Apr 15
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
2001 Apr 20
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
2001 Aug 15
Clear cell carcinoma of the ovary: a remarkable case.
2001 Feb
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
2001 Feb
Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.
2001 Feb
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
2001 Feb 1
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
2001 Feb 15
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
2001 Jan
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
2001 Jan
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
2001 Jul
Advances in the management of epithelial ovarian cancer.
2001 Jul
Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.
2001 Jul 1
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
2001 Jul 12
Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model.
2001 Jun-Jul
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
2001 Mar 12
Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
2001 May 10
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
2001 Sep
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
2001 Sep 1
Patents

Sample Use Guides

Ovarian cancer and small cell lung cancer: 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course. Cervical cancer: 0.75 mg/m2 by intravenous infusion over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m2 on Day 1
Route of Administration: Intravenous
In Vitro Use Guide
In DC3F hamster lung fibroblasts, 2.5 uM topotecan caused redistribution of topo I to nonnucleolar regions of the nucleus.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:15 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:15 GMT 2025
Record UNII
7M7YKX2N15
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOPOTECAN
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
HYCAMPTIN
Preferred Name English
NOGITECAN
Common Name English
topotecan [INN]
Common Name English
NSC-609699
Code English
TOPOTECAN [VANDF]
Common Name English
FF-10850 (liposomal topotecan)
Common Name English
1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, (4S)-
Systematic Name English
10-HYDROXY-9-((DIMETHYLAMINO)METHYL)-(20S)-CAMPTOTHECIN
Common Name English
TOPOTECAN [EMA EPAR]
Common Name English
Topotecan [WHO-DD]
Common Name English
HYCAMPTAMINE
Common Name English
SK&F-104864
Code English
TOPOTECAN [MI]
Common Name English
NSC-641007
Code English
SKF-104864
Code English
Classification Tree Code System Code
WHO-VATC QL01XX17
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS POTACTASOL (AUTHORISED: SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
FDA ORPHAN DRUG 694519
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: OVARIAN NEOPLASMS, SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS EVOTOPIN (WITHDRAWN: OVARIAN NEOPLASMS
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
LIVERTOX NBK548037
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN HOSPIRA (AUTHORISED: SMALL CELL LUNG CARCINOMA)
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN ACTAVIS (AUTHORISED: SMALL CELL LUNG CARCINOMA, UTERINE NEOPLASMS )
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
NDF-RT N0000000176
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: OVARIAN NEOPLASMS, SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
NDF-RT N0000175609
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
WHO-ATC L01XX17
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
NCI_THESAURUS C2843
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2707
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
DAILYMED
7M7YKX2N15
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
CHEBI
63632
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
INN
6783
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
NCI_THESAURUS
C1413
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
HSDB
8213
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
LACTMED
Topotecan
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
MERCK INDEX
m10977
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB01030
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
NSC
641007
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
IUPHAR
7101
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
EVMPD
SUB11191MIG
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
NSC
609699
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL84
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
WIKIPEDIA
Topotecan
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
PUBCHEM
60700
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
RXCUI
57308
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY RxNorm
SMS_ID
100000089213
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
MESH
D019772
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
CAS
123948-87-8
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
FDA UNII
7M7YKX2N15
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
EPA CompTox
DTXSID3042685
Created by admin on Mon Mar 31 17:59:15 GMT 2025 , Edited by admin on Mon Mar 31 17:59:15 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Km
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
Km
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Vmax
TRANSPORTER -> SUBSTRATE
Vmax
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
Topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide, were less than 2% of the administered dose.
URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY